Safety, tolerability and pharmacokinetics of multiple once-daily dosing of oral semaglutide in healthy males and in males with type 2 diabetes

被引：0
|
作者：
Granhall, C. [1 ]
Donsmark, M. [1 ]
Golor, G. [2 ]
Sondergaard, F. L. [1 ]
Thomsen, M. [1 ]
机构：
[1] Novo Nordisk, Soborg, Denmark
[2] Parexel Int, Berlin, Germany
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
790
引用
收藏
页码：S362 / S363
页数：2
相关论文
共 50 条
  • [41] Study of Once-Daily Levemir (SOLVE™): Safety and Efficacy of Once-Daily Insulin Detemir in Routine Clinical Practice in Chinese Patients With Type 2 Diabetes
    Pan, Changyu
    Lu, Juming
    Gao, Zhengnan
    DIABETES, 2012, 61 : A616 - A616
  • [42] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
    Iwamoto, Kazuya
    Nasu, Risa
    Yamamura, Ayuko
    Kothare, Prajakti A.
    Mace, Kenneth
    Wolka, Anne M.
    Linnebjerg, Helle
    ENDOCRINE JOURNAL, 2009, 56 (08) : 951 - 962
  • [43] A study of the pharmacokinetics and tolerability of ritipenem acoxil in healthy volunteers following multiple oral dosing
    Poggesi, I
    Spinelli, R
    Frigerio, E
    Benedetti, MS
    Carra, L
    Sassella, D
    Rimoldi, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) : 291 - 294
  • [44] Pharmacokinetics and tolerability of multiple-day oral dosing of mycophenolate mofetil in healthy horses
    Bello, Kaitlyn
    Lorch, Gwendolen
    Kim, Kyeongmin
    Toribio, Ramiro E.
    Yan, Liwei
    Xie, Zhiliang
    Hill, Kasey
    Phelps, Mitch
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2023, 37 (05) : 1907 - 1916
  • [45] Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes
    Sykes, A. P.
    Kemp, G. L.
    Dobbins, R.
    O'Connor-Semmes, R.
    Almond, S. R.
    Wilkison, W. O.
    Walker, S.
    Kler, L.
    DIABETES OBESITY & METABOLISM, 2015, 17 (01): : 98 - 101
  • [46] Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
    Seino, Yutaka
    Terauchi, Yasuo
    Osono, Takeshi
    Yabe, Daisuke
    Abe, Nobuyuki
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kaneko, Shizuka
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 378 - 388
  • [47] The safety, tolerability, pharmacokinetics and pharmacodynamics of NN414, a β-cell type (SURl/Kir6.2) potassium channel opener (KATPCO) following seven days once daily oral dosing in patients with type 2 diabetes
    Zdravkovic, M
    Kruse, M
    Ludwig, K
    Jacobsen, RJ
    Moss, J
    Kecskes, A
    DIABETES, 2002, 51 : A117 - A117
  • [48] Erratum to: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
    Juliana Levy
    Roberta A Cobas
    Marília B Gomes
    Diabetology & Metabolic Syndrome, 2
  • [49] Pharmacokinetics, safety, and tolerability of R411, a dual α4β1-α4β7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers
    Hijazi, Y
    Welker, H
    Dorr, AE
    Tong, FP
    Blain, R
    Renzetti, LM
    Abbas, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (12): : 1368 - 1378
  • [50] Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability-Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
    Markova, S.
    Baladi, M.
    Lee, M.
    Chen, C.
    MOVEMENT DISORDERS, 2024, 39 : S290 - S291
12345